Four Decades for Justice
Maggie Segall is a member of the Antitrust Practice. Her practice focuses on transactional matters, antitrust regulatory approval, government investigations and general antitrust counseling. She has advised a wide variety of clients in diverse industries, including aerospace and aviation, pharmaceuticals, life sciences, consumer products, media, manufacturing and technology.
Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:
Altra Industrial’s $5 billion acquisition by Regal Rexnord;
RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;
ADT’s $1.2 billion equity investment from State Farm;
Micro Focus’s $6 billion acquisition by OpenText Corp;
Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;
Additionally, Ms. Segall is representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 10 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint. She recently was part of the team representing Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history, securing a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The American Lawyer’s “Litigators of the Week.”
Ms. Segall has been repeatedly recognized for her antitrust work by Chambers USA and The Legal 500 US, including being recommended as a Leading Lawyer for antitrust merger control. She has been named to Crain’s New York Business’s list of “Notable Women in Law,” Bloomberg Law’s “40 Under 40” list and Global Competition Review’s “40 Under 40” list, which recognizes the top young antitrust lawyers in the world. Who’s Who Legal has also consistently recommended Ms. Segall for her antitrust work, including recently naming her the “Most Highly Regarded Future Leader” in Competition in North America. Benchmark Litigation has named Ms. Segall a “Future Star” and included her on its “40 & Under List,” and Lawdragon has included her on its “500 Leading Litigators in America” list. She was also recently recognized as one of Law360’s “Rising Stars” in Competition and received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.”
Ms. Segall is a Fellow of the American Bar Foundation and is a member of the International Bar Association’s, American Bar Association’s and the New York State Bar Association’s Antitrust Sections.
Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.
Ms. Segall joined Cravath in 2008 and was elected a partner in 2016.
Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:
Altra Industrial’s $5 billion acquisition by Regal Rexnord;
RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;
ADT’s $1.2 billion equity investment from State Farm;
Micro Focus’s $6 billion acquisition by OpenText Corp;
Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;
Additionally, Ms. Segall is representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 10 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint. She recently was part of the team representing Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history, securing a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The American Lawyer’s “Litigators of the Week.”
Ms. Segall has been repeatedly recognized for her antitrust work by Chambers USA and The Legal 500 US, including being recommended as a Leading Lawyer for antitrust merger control. She has been named to Crain’s New York Business’s list of “Notable Women in Law,” Bloomberg Law’s “40 Under 40” list and Global Competition Review’s “40 Under 40” list, which recognizes the top young antitrust lawyers in the world. Who’s Who Legal has also consistently recommended Ms. Segall for her antitrust work, including recently naming her the “Most Highly Regarded Future Leader” in Competition in North America. Benchmark Litigation has named Ms. Segall a “Future Star” and included her on its “40 & Under List,” and Lawdragon has included her on its “500 Leading Litigators in America” list. She was also recently recognized as one of Law360’s “Rising Stars” in Competition and received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.”
Ms. Segall is a Fellow of the American Bar Foundation and is a member of the International Bar Association’s, American Bar Association’s and the New York State Bar Association’s Antitrust Sections.
Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.
Ms. Segall joined Cravath in 2008 and was elected a partner in 2016.
American Bar Foundation
American Bar Association
International Bar Association
New York State Bar Association
Benchmark Litigation
Bloomberg Law
Chambers USA
Crain’s New York Business
Global Competition Review
Law360
Lawdragon
The Legal 500 US
Super Lawyers - New York
Who’s Who Legal
Americas Rising Star Awards - Best in Antitrust/Competition, Euromoney Legal Media Group (2018)
Deals & Cases
November 21, 2023
On November 20, 2023, Amentum, a portfolio company of Lindsay Goldberg and American Securities, announced a definitive agreement to merge with Jacobs’ Critical Mission Solutions and Cyber and Intelligence businesses, creating a new leader in systems integration and technology solutions. The transaction, which is structured as an all‑stock, Reverse Morris Trust transaction, will result in a publicly traded combined organization with $13 billion in revenue and more than 53,000 employees in 83 countries. Cravath is representing Amentum in connection with the transaction.
Deals & Cases
October 16, 2023
On October 16, 2023, Consolidated Communications Holdings, Inc. (“Consolidated Communications”), a top 10 fiber provider in the United States, announced it has entered into a definitive agreement to be acquired by affiliates of Searchlight Capital Partners, L.P. (“Searchlight”) and British Columbia Investment Management Corporation (“BCI”) in an all‑cash transaction with an enterprise value of approximately $3.1 billion, including the assumption of debt. Under the terms of the agreement, Searchlight and BCI will acquire all of the Consolidated common stock not already owned by Searchlight for $4.70 per share in cash. The proposed transaction has been unanimously approved by a special committee of independent and disinterested directors of Consolidated Communications’ Board of Directors (the “Special Committee”), advised by independent legal and financial advisors, formed to evaluate and consider the proposal and other potential strategic alternatives. The Board of Directors of Consolidated Communications, following recusals of directors affiliated with Searchlight and BCI, has approved the proposed transaction on the unanimous recommendation of the Special Committee. Cravath is representing the Special Committee in connection with the transaction.
Deals & Cases
October 16, 2023
On October 16, 2023, Vista Outdoor Inc. (“Vista Outdoor”), the parent company of 41 renowned brands that design, manufacture and market sporting and outdoor products to consumers around the globe, announced a definitive agreement to sell its Sporting Products business to Czechoslovak Group a.s. (“CSG”), a leading industrial technology holding company, for an enterprise value of $1.91 billion in an all-cash transaction. This transaction represents the next step in Vista Outdoor’s plan to split the company into separate entities. Cravath is representing Vista Outdoor in connection with the transaction.
Deals & Cases
October 02, 2023
On September 21, 2023, Cisco, a leading global technology company, and Splunk, a cybersecurity and observability leader, announced a definitive agreement under which Cisco intends to acquire Splunk for $157 per share in cash, representing approximately $28 billion in equity value. Cravath is representing Cisco on regulatory matters in connection with the transaction.
Deals & Cases
October 02, 2023
On October 1, 2023, Viatris Inc. (“Viatris”), a global healthcare company, announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (“OTC”) business, and has entered into definitive agreements to divest its Women’s Healthcare business, its Active Pharmaceutical Ingredient (“API”) business in India and commercialization rights in certain non-core markets that were acquired as part of the combination with Upjohn. The total transactions value, including Viatris’s 2022 divestiture of its biosimilars business, represents up to $6.94 billion of total gross proceeds. The estimated transaction value for the divestitures announced today is $3.6 billion, including gross consideration of up to approximately $2.17 billion for the divestiture of substantially all of its OTC business, and up to approximately $1.2 billion combined for the divestitures of its API and Women’s Healthcare businesses. Cravath is representing Viatris in connection with the transactions.
Activities & Publications
November 14, 2023
Cravath partner Margaret T. Segall authored a chapter entitled “Merger Remedies in Dynamic Industries” in Global Competition Review’s “Merger Remedies Guide – Fifth Edition,” which was published on October 25, 2023. The chapter, co‑authored by practice area attorney Nicole M. Peles, reviewed the common types of merger remedies, the characteristics of dynamic industries and challenges posed for traditional merger remedies. The chapter considered the different approaches adopted by antitrust authorities in creating remedies in the technology and pharmaceutical sectors, two rapidly evolving dynamic industries.
Activities & Publications
November 03, 2023
Cravath partners Margaret T. Segall, Nicholas A. Dorsey and G.J. Ligelis Jr. spoke at the International Bar Association’s 2023 Annual Conference, which was held from October 29 to November 3, 2023, in Paris and convened legal professionals from across the globe.
Activities & Publications
October 02, 2023
On September 29, 2023, Cravath partner Margaret T. Segall participated in “Hot Topics for In‑House Counsel 2023,” a program presented by the Practising Law Institute in New York. Maggie spoke on a panel entitled “The Evolving Domestic and International Antitrust Landscape,” which reviewed developments in the domestic and international antitrust landscape, including new approaches to mergers, conduct cases, remedies and potential legislative changes.
Activities & Publications
August 24, 2023
Cravath partner Margaret T. Segall and practice area attorney Nicole M. Peles authored a chapter entitled “US Merger Control in the Pharmaceutical Sector” for the 14th edition of The Merger Control Review, published as part of The Law Reviews series, which examines recent decisions, strategic considerations and upcoming developments of enforcement trends in different jurisdictions and sectors across the globe. Their chapter examines the Federal Trade Commission’s general review process for pharmaceutical mergers, their approach to merger remedies, and recent updates in their evaluation process.
Activities & Publications
July 28, 2023
On July 20, 2023, Cravath prepared a memo for its clients entitled “New Merger Guidelines and Recent Merger-Related FTC and DOJ Announcements.” The memo examines the Federal Trade Commission and the Department of Justice Antitrust Division’s recently proposed Merger Guidelines as well as recently proposed changes to the Hart-Scott-Rodino (HSR) filing process from the FTC and guidance concerning bank mergers from the DOJ. The memo outlines the thirteen Guidelines and their discussion of market definition, rebuttal evidence and approach to remedies. It also addresses what additional information the HSR filing proposals will require and summarizes Assistant Attorney General Jonathan Kanter’s recent speech concerning bank merger enforcement.
Maggie Segall is a member of the Antitrust Practice. Her practice focuses on transactional matters, antitrust regulatory approval, government investigations and general antitrust counseling. She has advised a wide variety of clients in diverse industries, including aerospace and aviation, pharmaceuticals, life sciences, consumer products, media, manufacturing and technology.
Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:
Altra Industrial’s $5 billion acquisition by Regal Rexnord;
RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;
ADT’s $1.2 billion equity investment from State Farm;
Micro Focus’s $6 billion acquisition by OpenText Corp;
Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;
Additionally, Ms. Segall is representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 10 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint. She recently was part of the team representing Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history, securing a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The American Lawyer’s “Litigators of the Week.”
Ms. Segall has been repeatedly recognized for her antitrust work by Chambers USA and The Legal 500 US, including being recommended as a Leading Lawyer for antitrust merger control. She has been named to Crain’s New York Business’s list of “Notable Women in Law,” Bloomberg Law’s “40 Under 40” list and Global Competition Review’s “40 Under 40” list, which recognizes the top young antitrust lawyers in the world. Who’s Who Legal has also consistently recommended Ms. Segall for her antitrust work, including recently naming her the “Most Highly Regarded Future Leader” in Competition in North America. Benchmark Litigation has named Ms. Segall a “Future Star” and included her on its “40 & Under List,” and Lawdragon has included her on its “500 Leading Litigators in America” list. She was also recently recognized as one of Law360’s “Rising Stars” in Competition and received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.”
Ms. Segall is a Fellow of the American Bar Foundation and is a member of the International Bar Association’s, American Bar Association’s and the New York State Bar Association’s Antitrust Sections.
Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.
Ms. Segall joined Cravath in 2008 and was elected a partner in 2016.
Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:
Altra Industrial’s $5 billion acquisition by Regal Rexnord;
RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;
ADT’s $1.2 billion equity investment from State Farm;
Micro Focus’s $6 billion acquisition by OpenText Corp;
Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;
Additionally, Ms. Segall is representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 10 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint. She recently was part of the team representing Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history, securing a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The American Lawyer’s “Litigators of the Week.”
Ms. Segall has been repeatedly recognized for her antitrust work by Chambers USA and The Legal 500 US, including being recommended as a Leading Lawyer for antitrust merger control. She has been named to Crain’s New York Business’s list of “Notable Women in Law,” Bloomberg Law’s “40 Under 40” list and Global Competition Review’s “40 Under 40” list, which recognizes the top young antitrust lawyers in the world. Who’s Who Legal has also consistently recommended Ms. Segall for her antitrust work, including recently naming her the “Most Highly Regarded Future Leader” in Competition in North America. Benchmark Litigation has named Ms. Segall a “Future Star” and included her on its “40 & Under List,” and Lawdragon has included her on its “500 Leading Litigators in America” list. She was also recently recognized as one of Law360’s “Rising Stars” in Competition and received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.”
Ms. Segall is a Fellow of the American Bar Foundation and is a member of the International Bar Association’s, American Bar Association’s and the New York State Bar Association’s Antitrust Sections.
Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.
Ms. Segall joined Cravath in 2008 and was elected a partner in 2016.
American Bar Foundation
American Bar Association
International Bar Association
New York State Bar Association
Benchmark Litigation
Bloomberg Law
Chambers USA
Crain’s New York Business
Global Competition Review
Law360
Lawdragon
The Legal 500 US
Super Lawyers - New York
Who’s Who Legal
Americas Rising Star Awards - Best in Antitrust/Competition, Euromoney Legal Media Group (2018)
Deals & Cases
November 21, 2023
On November 20, 2023, Amentum, a portfolio company of Lindsay Goldberg and American Securities, announced a definitive agreement to merge with Jacobs’ Critical Mission Solutions and Cyber and Intelligence businesses, creating a new leader in systems integration and technology solutions. The transaction, which is structured as an all‑stock, Reverse Morris Trust transaction, will result in a publicly traded combined organization with $13 billion in revenue and more than 53,000 employees in 83 countries. Cravath is representing Amentum in connection with the transaction.
Deals & Cases
October 16, 2023
On October 16, 2023, Consolidated Communications Holdings, Inc. (“Consolidated Communications”), a top 10 fiber provider in the United States, announced it has entered into a definitive agreement to be acquired by affiliates of Searchlight Capital Partners, L.P. (“Searchlight”) and British Columbia Investment Management Corporation (“BCI”) in an all‑cash transaction with an enterprise value of approximately $3.1 billion, including the assumption of debt. Under the terms of the agreement, Searchlight and BCI will acquire all of the Consolidated common stock not already owned by Searchlight for $4.70 per share in cash. The proposed transaction has been unanimously approved by a special committee of independent and disinterested directors of Consolidated Communications’ Board of Directors (the “Special Committee”), advised by independent legal and financial advisors, formed to evaluate and consider the proposal and other potential strategic alternatives. The Board of Directors of Consolidated Communications, following recusals of directors affiliated with Searchlight and BCI, has approved the proposed transaction on the unanimous recommendation of the Special Committee. Cravath is representing the Special Committee in connection with the transaction.
Deals & Cases
October 16, 2023
On October 16, 2023, Vista Outdoor Inc. (“Vista Outdoor”), the parent company of 41 renowned brands that design, manufacture and market sporting and outdoor products to consumers around the globe, announced a definitive agreement to sell its Sporting Products business to Czechoslovak Group a.s. (“CSG”), a leading industrial technology holding company, for an enterprise value of $1.91 billion in an all-cash transaction. This transaction represents the next step in Vista Outdoor’s plan to split the company into separate entities. Cravath is representing Vista Outdoor in connection with the transaction.
Deals & Cases
October 02, 2023
On September 21, 2023, Cisco, a leading global technology company, and Splunk, a cybersecurity and observability leader, announced a definitive agreement under which Cisco intends to acquire Splunk for $157 per share in cash, representing approximately $28 billion in equity value. Cravath is representing Cisco on regulatory matters in connection with the transaction.
Deals & Cases
October 02, 2023
On October 1, 2023, Viatris Inc. (“Viatris”), a global healthcare company, announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (“OTC”) business, and has entered into definitive agreements to divest its Women’s Healthcare business, its Active Pharmaceutical Ingredient (“API”) business in India and commercialization rights in certain non-core markets that were acquired as part of the combination with Upjohn. The total transactions value, including Viatris’s 2022 divestiture of its biosimilars business, represents up to $6.94 billion of total gross proceeds. The estimated transaction value for the divestitures announced today is $3.6 billion, including gross consideration of up to approximately $2.17 billion for the divestiture of substantially all of its OTC business, and up to approximately $1.2 billion combined for the divestitures of its API and Women’s Healthcare businesses. Cravath is representing Viatris in connection with the transactions.
Activities & Publications
November 14, 2023
Cravath partner Margaret T. Segall authored a chapter entitled “Merger Remedies in Dynamic Industries” in Global Competition Review’s “Merger Remedies Guide – Fifth Edition,” which was published on October 25, 2023. The chapter, co‑authored by practice area attorney Nicole M. Peles, reviewed the common types of merger remedies, the characteristics of dynamic industries and challenges posed for traditional merger remedies. The chapter considered the different approaches adopted by antitrust authorities in creating remedies in the technology and pharmaceutical sectors, two rapidly evolving dynamic industries.
Activities & Publications
November 03, 2023
Cravath partners Margaret T. Segall, Nicholas A. Dorsey and G.J. Ligelis Jr. spoke at the International Bar Association’s 2023 Annual Conference, which was held from October 29 to November 3, 2023, in Paris and convened legal professionals from across the globe.
Activities & Publications
October 02, 2023
On September 29, 2023, Cravath partner Margaret T. Segall participated in “Hot Topics for In‑House Counsel 2023,” a program presented by the Practising Law Institute in New York. Maggie spoke on a panel entitled “The Evolving Domestic and International Antitrust Landscape,” which reviewed developments in the domestic and international antitrust landscape, including new approaches to mergers, conduct cases, remedies and potential legislative changes.
Activities & Publications
August 24, 2023
Cravath partner Margaret T. Segall and practice area attorney Nicole M. Peles authored a chapter entitled “US Merger Control in the Pharmaceutical Sector” for the 14th edition of The Merger Control Review, published as part of The Law Reviews series, which examines recent decisions, strategic considerations and upcoming developments of enforcement trends in different jurisdictions and sectors across the globe. Their chapter examines the Federal Trade Commission’s general review process for pharmaceutical mergers, their approach to merger remedies, and recent updates in their evaluation process.
Activities & Publications
July 28, 2023
On July 20, 2023, Cravath prepared a memo for its clients entitled “New Merger Guidelines and Recent Merger-Related FTC and DOJ Announcements.” The memo examines the Federal Trade Commission and the Department of Justice Antitrust Division’s recently proposed Merger Guidelines as well as recently proposed changes to the Hart-Scott-Rodino (HSR) filing process from the FTC and guidance concerning bank mergers from the DOJ. The memo outlines the thirteen Guidelines and their discussion of market definition, rebuttal evidence and approach to remedies. It also addresses what additional information the HSR filing proposals will require and summarizes Assistant Attorney General Jonathan Kanter’s recent speech concerning bank merger enforcement.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. © 2023 Cravath, Swaine & Moore LLP.